comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 11:38:24 - browse：8117

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Senators push IRS to launch nonprofit hospital probe

WSS

CDC launches VaccineFinder tool to locate Covid

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Germany receives 178 compensation applications from gay servicepeople over discrimination

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Treatments for cramps don't cut it. Why aren't there better options?

explore

comprehensive

focus

As demand for Covid shots wanes, Moderna seeks its next success

Bird flu researchers hone in on Finland’s mink farms

State Dept. review finds Biden bears some blame for Afghanistan failures

Ohioans vote in high

Walensky prepares to leave CDC — and Congress — behind

Novo Nordisk touts Wegovy study, but still struggling with supply

How one medical school became remarkably diverse

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Illinois Supreme Court finds assault weapons ban constitutional

hotspot

Senators push IRS to launch nonprofit hospital probe

The painfully weak evidence on taking collagen to treat arthritis

Aspartame and sugar

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Aspartame and sugar

Wikipedia

knowledge

leisure time

entertainment